

DCF Psychotropic Medication Advisory Committee
Meeting Minutes
February 05, 2021, 1:00 PM

PRESENT via Video Conference: David Aresco RPh; Paul Rao, M.D.; Margaret Rudin, APRN, PhD; Laine Taylor, D.O.; Amy Veivia, Pharm.D.; Brian Keyes, M.D.; Carissa Patsky-Pomerleau, M.D.; Pamela Hetherington, M.D.; John Pitegoff, M.D.; Dielka Brutus, APRN; Tina Spokes, RN; Nicole Taylor, M.D.

1. The meeting was held remotely via ZOOM; Dr. Rao called the meeting to order at 1:06pm.
2. The next meeting is scheduled for March 05, 2021 from 1pm – 2:30pm as a remote meeting.
3. Minutes: The minutes of the December 2020 meeting will be reviewed at the next PMAC meeting.
4. Announcements: NONE
5. Medication therapeutic class review and discussion: Antianxiety medications and other sleep meds.
 - i. Research was conducted and the results presented to the Committee by Dr. Veivia.
 - ii. The current PMAC protocol for this medication class was distributed (via email), reviewed and discussed. No revisions were recommended.
 - iii. Additionally, 2 relevant articles were reviewed and discussed. These articles discussed the medications used for the various anxiety disorders. These were presented for informational purposes.
 - iv. There was a discussion regarding benzodiazepine use. Use among DCF youth is limited.
 - v. The drug class review schedule for 2021 was distributed, reviewed, and approved.
6. Standing items:
 - ❑ Obtaining vitals and laboratory tests and other assessments: deferred.
 - ❑ PRN statement in Monitoring Protocol: deferred.
 - ❑ PMAC contributions to discussions around implementation of FFPSA: deferred
7. NEW business:
 - ❑ Review of the Guidelines for Psychotropic Medication Use in Children and Adolescents. Each chapter was presented (including proposed edits), reviewed, and discussed in detail. Dr. Rao led this discussion.
 - i. Noted that the last update to these guidelines was in 2014.
 - ii. Changes to content and style were discussed. A second version with the discussed edits approved will be forwarded to the committee. Further discussion regarding specific wording will be discussed at the next meeting.

- iii. Standards of practice and best practice guidelines for psychotropic prescribing for foster youth to use as a reference and/or resource were discussed. Amy Veivia will research this subject and report back at the next PMAC meeting.
- iv. Adverse Drug Reaction Reporting: Section 5 of the guidelines addressed this. The current report process was reviewed and discussed. Noted this process does not seem to be effective/efficient as no ADR's have been reported. There was a brief discussion regarding side effects vs. ADR's. A recommendation was made to remove this section from the guidelines. A second recommendation was made to keep the subject of ADR reporting active by accessing and discussing Solnit North and South aggregate ADR data. Both recommendations were approved subject to verifying access to Solnit ADR aggregate data.

8. Other as time allows: NONE

9. Dr. Rao adjourned the meeting at 2:30PM.

Respectfully submitted: David S. Aresco Consulting Pharmacist